Keywords

leukemia, molecular mechanisms, genetic mutations, targeted therapy, immunotherapy, chemotherapy, drug resistance, stem cell transplantation, CRISPR technology, CAR T-cell therapy, personalized medicine, philadelphia chromosome, BCR- ABL fusion gene, FLT3 mutation, minimal residual disease, tyrosine kinase inhibitors